Vaginal clindamycin cream and clindamycin vaginal ovules are prescription formulations used in bacterial vaginosis (BV) care. They are delivered intravaginally, but the cream is a semisolid product measured by an applicatorful, whereas ovules are individual suppositories with a labeled amount of clindamycin. The distinction is meaningful when a prescription is filled, not merely a difference in appearance.
U.S. guidance includes conventional clindamycin cream 2% as a recommended BV regimen and 100 mg clindamycin ovules among alternative regimens. Those clinical categories do not establish that an individual should replace a cream with ovules, repeat an old course or choose a shorter schedule without evaluation. For general products, see the vaginal cream guide and ovule product guide.
The label also matters for precautions that are easy to overlook. Both conventional Cleocin vaginal cream and Cleocin vaginal ovules warn that ingredients in their formulations can weaken latex or rubber barrier contraception during the specified period following treatment. This article compares the conventional products and does not substitute a separate discussion of Clindesse single-dose cream or Xaciato gel.
The primary difference is formulation and the physical unit dispensed. One should not compare the number “100 mg” on an ovule carton with the “2%” on a cream tube as if both were dose-selection instructions. A 5 g applicatorful of standard 2% cream corresponds to approximately 100 mg of clindamycin on its representative label, but the delivery system and regimen are still different.
The table reflects conventional branded U.S. labels and CDC treatment context; it does not decide which treatment suits a patient. Selection depends on the diagnosis, prescription and contraindications.
| Question | Conventional vaginal cream 2% | Vaginal ovules 100 mg |
|---|---|---|
| Dosage form | Intravaginal semisolid cream | Intravaginal suppository |
| Strength designation | 2% clindamycin equivalent (20 mg/g) | 100 mg clindamycin per ovule |
| Delivery | Vaginal applicatorful measured from cream | Individual suppository inserted as labeled |
| CDC treatment context | Clindamycin cream appears among recommended BV regimens | Clindamycin ovules appear among alternative BV regimens |
| Typical labeled regimen reference | Standard cream regimen uses several administrations | Ovule regimen uses individual suppositories on labeled days |
| Barrier precautions | Mineral oil may weaken latex/rubber; 72-hour restriction after therapy | Oleaginous base may weaken latex/rubber; 72-hour restriction after therapy |
The 2% cream contains clindamycin phosphate equivalent to 20 mg clindamycin per gram of cream. A full standard applicator of 5 g delivers approximately 100 mg of clindamycin. The ovule is labeled as a 100 mg vaginal suppository. These facts explain product identity, not permission to exchange one application for one suppository.
A prescription should specify the form and directions. Patients should not calculate a new regimen from weight, percentage or product count. The pharmacist must dispense the authorized formulation.
CDC guidance identifies intravaginal clindamycin cream as one of the recommended BV treatment options and the 100 mg suppository among alternatives. The placements reflect guideline considerations, not a patient-facing ranking or proof that either formulation is appropriate for every episode of symptoms.
Symptoms that resemble BV can have other causes, including sexually transmitted infections or yeast infection. The clindamycin for BV clinical guide explains why diagnosis is needed rather than self-selecting the medicine from a pharmacy listing.
Standard vaginal cream typically comes in a tube used with provided applicators; a course requires reading how the labeled applicator is filled and what components are supplied. Ovules arrive as individual suppositories rather than a cream to measure. An incorrect product name or missing delivery component can disrupt the intended instructions.
Compare the product type and package count on the prescription with the pharmacy carton before leaving. If a pharmacy proposes a different form because of inventory, the prescriber should assess whether a change is suitable.
Cleocin vaginal cream contains mineral oil, and Cleocin ovules use an oily base. Their labels warn that latex or rubber condoms and vaginal diaphragms may be weakened, so these products are not recommended within 72 hours after the respective treatment. The limit is formulation-specific; it is not a general rule for every vaginal gel.
Barrier-method questions may affect both pregnancy prevention and protection from sexually transmitted infections. Ask a clinician or pharmacist about alternatives rather than assuming a latex product remains reliable during the restricted period.
Vaginal treatments can cause local discomfort, irritation or yeast overgrowth, and some clindamycin is absorbed systemically. Clinically important diarrhea and colitis are warning considerations even though the medication is not swallowed. A history of antibiotic-associated colitis or inflammatory bowel conditions is particularly relevant under the conventional Cleocin vaginal labels.
Report severe persistent diarrhea, blood in stool or significant abdominal pain promptly. See the C. difficile safety explanation for symptom timing and when to seek evaluation.
Pregnancy status, allergies, recurrent symptoms, other vaginal therapies and the possibility of another infection can change clinical decision-making. These issues are not settled by comparing package convenience. The prescriber may need to confirm the diagnosis or select a more appropriate treatment framework.
Do not use a different person’s prescription, replace a vaginal ovule with a skin cream or apply products on non-labeled routes. Product instructions must be interpreted for the exact medicine supplied.
A branded Cleocin label and a generic vaginal clindamycin listing may differ in package language and supplied components, even when corresponding active drug and form information matches. Ask the pharmacist to identify the manufacturer, delivery system and prescription-compatible substitution rules.
Brand information is covered on the Cleocin vaginal cream page and Cleocin ovule brand page. Neither source should be treated as proof that a specific brand is currently in stock.
The price of a tube and a carton of suppositories reflects different package systems, amounts, brand or generic status and insurance rules. A quote per gram or per ovule does not compare complete prescribed courses or establish clinical superiority.
For an evergreen discussion of cost factors, use the vaginal clindamycin price guide. In a pharmacy discussion, first confirm the prescribed form and quantity; then request the current quote for that exact item.
A useful pharmacy conversation begins with a complete product description rather than asking simply whether “clindamycin vaginal” is stocked. Is the order for conventional 2% cream in a tube, 100 mg ovules in individually packaged units or another vaginal product? Is the required delivery system included, and does the package match the directions from the prescriber? If the expected package appears different, the pharmacist can contact the clinician instead of constructing an equivalent regimen from percentages or milligram figures. This is especially important when instructions from a previous course are still at home.
The conversation should also cover recent antibiotic-associated colitis, current vaginal symptoms, pregnancy or breastfeeding when relevant, and planned reliance on latex or rubber barriers. A patient who has been advised to use condoms for infection prevention may need product-specific counseling during the treatment period. Confirming these questions before dispensing is more useful than declaring that cream is a cheaper or more convenient version of an ovule. The formulations serve a clinician-selected plan, not a consumer-led interchange.
No. The cream is a measured semisolid preparation and the ovule is a discrete 100 mg suppository. Their regimens and dispensing systems differ.
Yes. U.S. treatment guidance includes conventional clindamycin cream and 100 mg vaginal ovules in different regimen categories.
A representative 5 g applicatorful of standard 2% cream contains approximately 100 mg clindamycin. That does not make it interchangeable with one ovule.
Do not change the prescribed vaginal form or regimen on your own. Contact the prescribing clinician for an individualized plan.
Yes. Representative Cleocin labels warn that the cream or ovule base may weaken latex or rubber barriers, including for 72 hours after treatment.
No. Clindesse is a separately labeled single-dose cream, while the conventional Cleocin cream has its own regimen and packaging.
No. Clindamycin vaginal ovules are for intravaginal use only and are not oral capsules.
Vaginal flora can change during antibacterial treatment, and yeast symptoms can occur. A clinician can assess new or persistent symptoms.
Confirm vaginal route, cream or ovule dosage form, labeled strength, complete package, instructions and prescription identity.